
|Videos|December 10, 2016
Combination of Veliparib and Chemotherapy in BRCA-Positive Breast Cancer
Author(s)Hyo Sook Han, MD
Hyo Sook Han, MD, medical oncologist, Moffitt Cancer Center, discusses results of the phase II BROCADE trial, which evaluated the combination of the PARP inhibitor veliparib with carboplatin/paclitaxel in patients with <em>BRCA</em>-positive breast cancer.
Advertisement
Hyo Sook Han, MD, medical oncologist, Moffitt Cancer Center, discusses results of the phase II BROCADE trial, which evaluated the combination of the PARP inhibitor veliparib with carboplatin/paclitaxel in patients withBRCA
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
NCCN Guidelines in nccRCC Weigh New Data for Combinations
3
CARTITUDE-4: Cilta-Cel May Offer Curative Potential in Standard-Risk R/R Myeloma
4
Microbiota-Based MaaT013 Shows Strong Efficacy in Refractory GI-aGVHD
5






































